Welcome Original


We deliver lines worldwide.

NHCDR iPSC Line Approved for Use in Clinical Trial

Our collaborator NeuroLINCS provides datasets for research on motor neuron iPSCs using epigenomics, transcriptomics, proteomics, and robotic imaging

previous arrow
next arrow

About Us

The National Institute of Neurological Disorders and Stroke (NINDS) is committed to providing well characterized cell sources to both academic and industry investigators to advance the study of neurological disorders.  Cell sources currently include fibroblasts and/or induced pluripotent stem cells for Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Ataxia-telangiectasia, Frontotemporal Lobar Degeneration (FTD), Huntington’s Disease, Parkinson’s Disease, and healthy controls.  Cell sources, including isogenic cell lines for current and new diseases covered by the NINDS will be added over the next several years.  Visit our catalog application to view the catalog and order lines.

All induced pluripotent stem cell (iPSC) lines previously available through the NINDS Repository at Coriell, as well as new iPSC lines recently developed by the NHCDR are now available through the NHCDR catalog.  Fibroblasts previously available through the NINDS Repository at Coriell will be available in May – June, 2016.  Human cell lines being analyzed by the NeuroLINCS data and cell signature generation center (DCSG), one of six DCSGs which are part of the National Institutes of Health (NIH) Library of Integrated Network-based Cellular Signatures (LINCS) program will be available in 2016.  Feel free to contact us for more information about the NHCDR.

The NHCDR has shipped thousands of lines across the globe.